Who's Observing The Observers—Cleaning Up The AI Mess In Aisle Seven

Today's news, that Coralogix closed a $115M funding round at a $1B valuation to disrupt observability with agentic AI, made we wonder — shouldn't C-Suite Leaders know who is observing the observers?
For some, it's been exciting to watch AI progress at lightning speed over the past few years. For others, the pace is exhausting, including those covering it, enterprises aiming to put it to productive work, and vendors striving to develop the tech or integrate it into their stacks.
Investors have been pouring in money at an impressive rate. A Crunchbase report documented the rise in startup funding last year which was dominated by investments in AI. According to their data: 'Close to a third of all global venture funding went to companies in AI-related fields, making artificial intelligence the leading sector for funding. Funding to AI-related companies reached over $100B — up more than 80% year over year from $55.6B in 2023.'
About a third of this went to foundation model companies. The rest flowed to related sectors like IT infrastructure needed to run AI, and those segments that rely on AI: autonomous vehicles, healthcare, robotics, etc. Want details? Stanford University reported that GenAI funding soared in 2024. Look for these numbers to jump again, with a continued march of funding rounds and M&A deals ahead.
These trends are probably not surprising. After all, even though the category has seen strong investments over the last ten years, close to $.5T, AI innovation presents a major inflection that is having a ripple effect across most all sectors. And GenAI and LLMs are the poster kids for the leaps we are seeing.
But news from IT observability vendor Coralogix, about a $115M E Round at +$1B valuation, showed that some smart money is finding its way to the technology needed to manage the mess we are creating. Yes, there can be some delight at the nexus of the less sexy areas of IT performance and AI safety - both of which are linchpins to further maturation and adoption of AI in the enterprise.
Why Observing The Observers Really Matters
The news relates to an area of IT that some may not be familiar with; so, I'll explain. Observability is the ability to understand the state of a system by examining the data it generates. The tech emerged from the software engineering and network monitoring worlds, as a response to the challenges of managing increasingly complex environments driven by the growth of cloud and distributed computing.
Basically, what it does is hoover in all the data 'exhaust fumes' generated by logs, metrics and traces, to make better sense of what is happening and help site reliability engineers (SREs) reduce outages and improve system health and reliability. The technology has evolved to take on more tasks, including application performance monitoring and security - encroaching on these spaces and sometimes integrating with the technologies.
Today, IT observability is a dynamic, highly competitive, and rapidly growing segment of enterprise IT. According to Gartner, the market is expanding at a compound annual growth rate (CAGR) of over 15%, with projections placing its total size at around $11.2 billion by 2026
I said that its evolution is a result of growing IT complexity and that AI adds an inflection, and some would argue, more complexity to the enterprise. At the same time, we all know that AI can help in managing things and drive better understanding of complex issues. What happens when AI meets observability?
Taking On The Big Dogs Of Observability
This brings us to today's news, which is a shot across the bow by Coralogix against the big dogs, not just metaphorically but also literally: e.g., Datadog, Dynatrace, New Relic, AppDynamics, Splunk and Acceldata.
These vendors help manage AI and use some form of it (e.g., machine learning or LLMs) in their stacks. They are also bullish about combining AI and observability. For example, on recent earning calls, Datadog CEO Josh Pomel said, "We continue to see rising customer [demand]
It seems Coralogix is taking a more aggressive approach. The company acquired AI observability provider Aporia last year, which resulted in the launch of their AI Center; the first solution to treat AI as a separate observability stack. Their AI Center helps manage not only AI performance, as some others do, but also its content, enabling businesses to detect hallucinations, toxicity, prompt injection (yeah that's a thing), and more.
Now, Coralogix has secured a major investment that should fuel its drive to disrupt the space with the first AI agent that extends observability value across the enterprise.
Why is this significant to C-Suite Leaders? First, from a sheer numbers PoV, it is a big round. While not the largest in AI by any stretch, it is an impressive amount for an up-and-comer that is not aiming to move mountains in the capital-intensive LLM and chips arenas.
I spoke with Coralogix CEO Ariel Assaraf about the news and their current status. He did not provide hard revenue numbers but said that the company has achieved impressive 72% YoY growth for the last three years. Customers include well-known logos like Adobe Systems, Ferrari and DoorDash.
This round was led by CA-based venture growth firm NewView Capital. Ariel shared that all existing investors including Advent International, Brighton Park Capital, Revaia, and Greenfield Partners, returned to support Coralogix's continued growth and launch into agentic AI observability.
'Decoder Ring' Knocks Down Tower Of Babel Separating Business And IT
Interestingly, they issued a second and related announcement at the same time: 'Coralogix Unveils Industry's First AI Agent That Extends Observability Value Across the Enterprise.'
When I asked Ariel Assaraf to connect the dots; he said: "We have this unique architecture that allows teams to ingest more data, analyze the data in-stream, and make informed decisions for optimization. Traditional observability is super-expensive and doesn't scale; we fixed that. Now we're adding agentic AI, and people can make informed decisions across business units without being experts."
He further explained: "AI introduces new challenges around data security, accuracy, and scale, demanding a new approach. Agentic AI can enable smarter observability that minimizes manual effort and makes it easier for teams to surface and act on insights from their data.'
According to the press release, their agent, called 'Olly,' is an agentic AI that transcends the more typical event alerts observability platforms generate to answer questions and provide guidance.
This sounds like they are tackling the disconnect that can occur between the business and IT sides. It's the old business and IT alignment challenge that has yet to be solved. One of the biggest barriers is the translation gap — non-technical stakeholders can't easily understand 'geek speak' or explore how backend systems impact business outcomes.
With Olly, both technical and non-technical users can ask questions in plain English, from 'What is wrong with the payment flow?' or 'Why do some users struggle with logging in?' to more holistic questions like 'Which service is frustrating our users the most?' In short, democratizing insights available from observability, to better connect IT performance and drive smarter outcomes, is what enterprises need now.
As AI-enabled observability becomes more mainstream in the enterprise, look for impacts across the organization — from frontline performers to boardroom risk mitigators. Like other tech trends I've unpacked, which are critical for the next generation of C-Suiters to lead their organizations, keep an eye on the observers to help you better align the tech and business goals — and hopefully boost results across your enterprise.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

24 minutes ago

• Yahoo

2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts

These biotech companies have several catalysts ahead -- and in the past have soared on good news. They both offer innovative candidates that could result in game-changing treatments for patients. 10 stocks we like better than Viking Therapeutics › If you're looking to add growth to your portfolio, biotech stocks can be a great choice. Exciting research is happening in these companies' labs, and in some cases, game-changing treatment candidates are approaching important milestones or even going over the finish line. As an investor in these companies, you can benefit as they report positive clinical trial news, score a regulatory approval, or start generating product revenue. Wall Street considers two candidates extremely compelling right now, with forecasts for potential gains of more than 80% and 200% in the coming 12 months. One of these players is working in the high-growth area of weight loss drugs, and the other candidate showed its strengths by winning the world's first-ever approval of a product based on CRISPR gene editing. Let's check out these two biotech stocks to buy before they skyrocket. Viking Therapeutics (NASDAQ: VKTX) soared early last year when it reported strong data from the phase 2 trial of its weight loss candidate, VK2735, but the stock has since given back those gains and is trading closer to the level it was at prior to that data announcement. Since, the company has continued to advance VK2735 in injectable form and a version in pill form, and demand for these sorts of drugs remains high -- these are two reasons to believe that Viking has the potential to take off again. And catalysts may be on the horizon. The drug works in a manner similar to Eli Lilly's blockbuster tirzepatide, sold under the names Mounjaro and Zepbound. These drugs interact with hormones involved in digestion and have helped people quickly and safely lose weight. Viking is beginning the phase 3 trial for injectable VK2735 in the second quarter and expects data from its phase 2 trial of the pill version in the second half. Any data announcements could result in big moves for the stock, as there is plenty of room for a new company to enter the weight loss drug market -- one forecast to approach $100 billion in a few years. Wall Street is optimistic about Viking's prospects, with the average price forecast predicting an increase of about 240% in the stock price from today's level. Of course, Viking depends heavily on the outcome of these trials, so some risk is involved -- but data have been strong, so growth investors may want to get in on Viking now to potentially post a big win later. CRISPR Therapeutics (NASDAQ: CRSP) stock surged in the year leading up to a major milestone: its first product approval. But since last year's launch of Casgevy, a gene-editing treatment for blood disorders, the stock has been on the decline. Sometimes, investors buy a stock well before the company wins approval or launches a product, then lock in gains after the good news lands -- and I think this is what's happened here. But what this does is offer us a chance to get in at a very good price on a promising company that could deliver fantastic news down the road. Casgevy, as a gene-editing treatment, requires a longer time to roll out than a pill or injection, as it includes several steps that happen over a period of months. The company recently said new patient initiations should increase "significantly" this year -- so there's reason to be optimistic about revenue growth ahead. CRISPR Therapeutics also recently reported positive phase 1 data for a gene editing candidate addressing the problem of high cholesterol. And the company expects to report data soon from a phase 1 trial of a candidate targeting patients with elevated levels of lipoprotein(a) -- a risk factor for cardiovascular events. These could represent huge markets for CRISPR Therapeutics if the candidates reach the finish line, and in the meantime, any potential positive news could boost the stock. The company also expects other trial updates in candidates for oncology and autoimmune diseases this year -- so this biotech's calendar is full of possible catalysts. Wall Street's average price forecast calls for an 84% gain for CRISPR Therapeutics from today's price -- if all goes well in clinical trials and Casgevy starts to show revenue growth, now could represent a golden buying opportunity for growth investors. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CRISPR Therapeutics. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. 2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

27 minutes ago

• Yahoo

Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Dan Ives' new artificial intelligence exchange-traded fund (ETF) holds securities beyond the Magnificent 7 stocks, as he believes in looking past valuations for investments in the technology sector. What Happened: The Dan IVES Wedbush AI Revolution ETF (NYSE:IVES), managed by the Wedbush analyst, started trading on June 4, earlier this month. Ives boasts of the fund by saying that it just doesn't have the top four, five Magnificent 7 names, but stocks which investors wouldn't even thematically consider as an AI name today. "I believe the market is still massively underestimating what the growth is going to look like for the AI revolution in tech," he told CNBC. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — According to him, tech trade remains significant even for the investors who missed out on its growth in the past few years. "If you focus just on valuation, you miss every transformational tech stock of the last 20 years," Ives said. Ives says Oracle Corp. (NYSE:ORCL) will be the 'epicenter' of the AI theme, while highlighting other 'AI 30' stocks which are part of his fund. Palantir Technologies Inc. (NASDAQ:PLTR), International Business Machines Corp. (NYSE:IBM), Salesforce Inc. (NYSE:CRM), SoundHound AI Inc. (NASDAQ:SOUN), and Innodata Inc. (NASDAQ:INOD) are a few notable names that are a part of his ETF's 'AI 30' basket. Microsoft Corp. (NASDAQ:MSFT), Nvidia Corp. (NASDAQ:NVDA), and Broadcom Inc. (NASDAQ:AVGO) are the top three holdings of the IVES It Matters: The 'AI 30' stocks, which are a part of the IVES ETF, hold the AI plays from multiple industries. They include hyperscalers, cybersecurity, consumer platforms, and robotics. According to Ives, the list was compiled from his deep dives into major AI players. The ETF has $183 million in assets under management as of June 17 close. Ives said that the AI space was experiencing a "golden age." The Dan IVES Wedbush AI Revolution ETF has risen by 2.76% since its inception. A comparable index, S&P Kensho Global Artificial Intelligence Enablers, rose 6.08% on a month-to-date basis. Meanwhile, the SPDR S&P 500 ETF Trust (NYSE:SPY) and Invesco QQQ Trust ETF (NASDAQ:QQQ), which track the S&P 500 index and Nasdaq 100 index, respectively, declined slightly on Wednesday. The SPY was down 0.015% at $597.44, while the QQQ was 0.017% lower at $528.99, according to Benzinga Pro data. Read Next: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it? Photo courtesy: Shutterstock This article Dan Ives Says Market Is 'Massively Underestimating' This AI Play, Urges Investors To Look Beyong Mag 7 originally appeared on

Forbes

28 minutes ago

• Forbes

Google's Quiet Confirmation Of The Pixel 10

Google's "Talking Phones Podcast" title card Google is having a little bit of fun in its latest iPhone vs Pixel video. While the Pixel 9 Pro takes pride of place, there's also a surprising cameo for what comes next… the Pixel 10. The Pixel 10 Easter Egg The details come at the end of Google's latest promotional video posted on its Made By Google YouTube channel. In it, an iPhone and a Pixel talk about the recent advances made by Apple's smartphone, with a not at all surprised Pixel noting when that feature arrived on Pixel and Android. These include live translation, hold assistance and call screening arriving four, five and seven years ago respectively., Of course, the capabilities of all these features have improved significantly over the last few years, so there are shades of Oranges to (ahem) Apples here, but it makes Google's point effectively. The story of Android being ahead of iOS is here for all to hear. The little easter egg at the end is part of another story, leading into the next Pixel release. The iPhone quietly asks the Pixel 9 Pro, 'so, what are you working on for Pixel 10… just out of curiosity?' Naming The Pixel 10 It's no secret that Google is working on the next family of Pixel smartphones. Neither is it a secret that we're expecting an entry-level Pixel 10, a premium Pixel 10 Pro, a larger Pixel 10 Pro XL and an innovative Pixel 10 Pro Fold. Yet this is the first time Google has publicly acknowledged that the new handsets will carry the Pixel 10 branding. Although the sharp-eared watchers will note that it was the iPhone confirming the new Pixel 10, not the Pixel 9 Pro. So, did Apple confirm the new name, rather than Google? Google is expected to announce the Pixel 10 family at an upcoming Made By Google event. While dates have not been confirmed, talk within the community picks out Wednesday, Aug. 20 for the launch, and Thursday, Aug 28. for the first handsets to go on sale to the public. Now read how the Pixel 10 will impact every Android smartphone in 2025 and beyond…